Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹223.76
19.65 (9.63%)
High VOLATILITY
As on 12 Jun 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹7.26K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
4.3
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹108+107.2%
52W High₹248.75-10.0%
Current Price
₹223.76
Circuit Limits (10%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹201.38
Upper Circuit₹246.14
Reference Price
₹223.76
Investment Checklist
Rounding Bottom on 1W (BREAKOUT CONFIRMED) — target ₹168.51
Triple Bottom on 1D (BREAKOUT CONFIRMED) — target ₹160.8
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 50.56 (BUY) with 55.1% confidence
Volume divergence: Bearish (price up, volume down)
Technical Analysis
Technical Analysis
Analysis from 2026-06-12
Confidence
55%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
200.68
EMA50
177.57
EMA200
152.2
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows6
Lower Highs4
Lower Lows3
Support & Resistance Levels
Resistance (Above)
₹248.75
Support (Below)
₹194.10
₹182.59
₹179.43
₹172.80
₹166.46
Volume Analysis
TrendDECREASING
Change-79.10%
Unusual VolumeNo
Divergence Detected
Bearish (price up, volume down)
Stop Loss Levels
Fixed Risk
1% Risk₹221.52
3% Risk₹217.05
5% Risk₹212.57
7% Risk (Custom)
₹208.10Technical Levels
1x ATR (Volatility)₹210.09
2x ATR (Swing)₹196.42
3x ATR (Trend)₹182.75
Immediate Support₹194.10
Moving Averages
EMA 9 (Short-term)₹209.90
EMA 20 (Medium-term)₹200.68
EMA 50 (Trend)₹177.57
EMA 200 (Long-term)₹152.20
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹27.2 Cr | ₹9.6 Cr | ₹7.9 Cr | ₹8.5 Cr |
| Net Profit | ₹-59.8 Cr | ₹-51.9 Cr | ₹-75.9 Cr | ₹-80.4 Cr |
| EPS | — | ₹-1.60 | ₹-2.34 | ₹-2.48 |
| Operating Profit | ₹-53.7 Cr | ₹-42.9 Cr | ₹-65.7 Cr | ₹-69 Cr |
ROE
157.88%
ROCE
-693.64%
Debt/Equity
-1.22
Current Ratio
0.07
OPM
-816.57%
NPM
-951.72%
Peer Comparison
PharmaceuticalsPeer Comparison
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | ₹1,807.70 | +0.75% |
| DIVISLAB | Divi's Laboratories Limited | ₹6,638.00 | -0.26% |
| TORNTPHARM | Torrent Pharmaceuticals Limited | ₹4,571.20 | -0.02% |
| CIPLA | Cipla Limited | ₹1,389.40 | +0.44% |
| ZYDUSLIFE | Zydus Lifesciences Limited | ₹1,104.70 | -0.11% |
| DRREDDY | Dr. Reddy's Laboratories Limited | ₹1,275.40 | -0.05% |
| LUPIN | Lupin Limited | ₹2,293.30 | +0.88% |
| MANKIND | Mankind Pharma Limited | ₹2,381.10 | +0.35% |
| AUROPHARMA | Aurobindo Pharma Limited | ₹1,472.80 | +0.59% |
| LAURUSLABS | Laurus Labs Limited | ₹1,394.30 | +0.25% |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 21 Sept 2021 | Annual General Meeting | AGM |
| 22 Sept 2020 | Annual General Meeting | AGM |
| 18 Jul 2019 | Annual General Meeting | AGM |
| 19 Jul 2018 | Annual General Meeting | AGM |
| 27 Jul 2017 | Annual General Meeting | AGM |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
No upcoming events found
We couldn't find any scheduled corporate actions for this symbol at the moment.
Latest News
News for SPARC
View All
positive
CNBC TV18 - Markets 1d ago
Anupam Rasayan becomes first company to commercialise ETFA, eyes $500 million market
Anupam Rasayan said it will continue to invest in advanced process technologies, research capabilities and sustainable manufacturing practices as part of its long-term growth strategy.
ANURASLTGILTBEESSPARCChemicalsFinancial Services
neutral
ET Markets - Stocks 1d ago
Sun Pharma Share Price Live Updates: Sun Pharma's stock faces a monthly decline
ARSSBLSPARCFinancial ServicesHealthcare
NEWS
positive
Business Standard - Markets 2d ago
Alembic Pharma gains after receiving USFDA nod for Larotrectinib Capsules
Alembic Pharmaceuticals advanced 1.15% to Rs 744.95 after the company announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Larotrectinib Capsules.
ALEMBICLTDAPLLTDSPARCHealthcareRealty